Comparative Pharmacology
Head-to-head clinical analysis: CLARINEX D 24 HOUR versus CLEMASTINE FUMARATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARINEX D 24 HOUR versus CLEMASTINE FUMARATE.
CLARINEX D 24 HOUR vs CLEMASTINE FUMARATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desloratadine is a long-acting tricyclic histamine antagonist with selective peripheral H1-receptor antagonist activity. Loratadine is a long-acting antihistamine that selectively antagonizes peripheral H1-receptors.
Clemastine fumarate is a competitive antagonist of histamine at H1-receptor sites, suppressing histamine-induced vasodilation, increased capillary permeability, bronchoconstriction, and pruritus. It also exhibits anticholinergic and sedative effects.
1 tablet (5 mg desloratadine/120 mg pseudoephedrine) orally once daily
1.34 mg orally twice daily; max 8.04 mg/day
None Documented
None Documented
Desloratadine: terminal t1/2 27 hours (range 20-50h) supporting once-daily dosing. Pseudoephedrine: t1/2 5-8 hours (up to 16h in alkaline urine).
Terminal elimination half-life: 21 ± 6 hours. Provides sustained antihistamine effect, allowing twice-daily dosing.
Desloratadine: ~87% excreted as metabolites (41% urine, 43% feces), <2% unchanged. Pseudoephedrine: ~70-90% excreted unchanged in urine.
Primarily renal (45-55% as unchanged drug and metabolites) and fecal (30-40%), with biliary excretion contributing minorly.
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine